PMID: 11607044Oct 19, 2001Paper

Fluvoxamine as an adjunctive agent in schizophrenia

CNS Drug Reviews
H Silver

Abstract

Schizophrenia is a common mental disorder that has an early onset and rates high as a cause of medical disability. Antipsychotic agents are the mainstay of treatment but response is often inadequate. Negative symptoms (disturbances in volition, social interaction and affective functions) are particularly difficult to treat and form a major obstacle to rehabilitation. A promising approach to improve response of negative symptoms has been to add a selective serotonin reuptake inhibitor (SSRI) antidepressant to antipsychotic treatment. This review examines evidence pertaining to the efficacy, tolerability, and safety of the SSRI fluvoxamine, combined with antipsychotic agents, in the treatment of negative symptoms in schizophrenia. Important methodological issues, such as differentiating primary and secondary negative symptoms, are discussed. The balance of available evidence indicates that fluvoxamine can improve primary negative symptoms in chronic schizophrenia patients treated with typical antipsychotics and suggests that it may also do so in some patients treated with clozapine. This combination is generally safe and well tolerated although, as antipsychotic drug concentrations may be elevated, attention to dose and drug moni...Continue Reading

References

Sep 1, 1978·Archives of General Psychiatry·T Van Putten, R P May
Aug 1, 1977·British Journal of Pharmacology·V ClaassenP Placheta
Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Dec 1, 1992·Therapeutic Drug Monitoring·M H de VriesJ van Harten
Aug 1, 1992·The Journal of Nervous and Mental Disease·J KuckD L Braff
Sep 1, 1992·Trends in Pharmacological Sciences·F J Gonzalez
Mar 1, 1992·Archives of General Psychiatry·W S Fenton, T H McGlashan
Mar 1, 1992·Schizophrenia Research·D AddingtonJ Joyce
Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·L HernandezB G Hoebel
Jul 1, 1990·Schizophrenia Research·D AddingtonB Schissel
Mar 1, 1990·Psychiatry Research·J W NewcomerJ G Csernansky
Jul 1, 1990·Archives of General Psychiatry·N C AndreasenS Arndt
Jul 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·A M MortimerP J McKenna
Jan 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Apr 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R BarnesM Patel
May 1, 1989·Schizophrenia Research·S R HirschM Patel
Nov 1, 1989·Psychiatry Research·B KirkpatrickW T Carpenter
Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Feb 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·P KulharaS Joseph
Jan 1, 1985·Schizophrenia Bulletin·W T CarpenterL D Alphs
Dec 1, 1988·The American Journal of Psychiatry·S G SirisE Casey
Dec 1, 1987·The American Journal of Psychiatry·T L PerseR Dar
Apr 1, 1987·Acta Psychiatrica Scandinavica·R C BlandH Orn
Jan 1, 1987·Psychiatry Research·S ThiemannP A Berger
Jul 1, 1987·Archives of General Psychiatry·D R Weinberger
Sep 1, 1985·Psychiatry Research·A C IagerR J Wyatt
Apr 1, 1986·The American Journal of Psychiatry·W S Fenton, T H McGlashan
Jan 1, 1985·Schizophrenia Bulletin·A A Sommers
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Sep 1, 1982·Journal of Affective Disorders·J E De Wilde, D P Doogan
Jan 1, 1983·British Journal of Clinical Pharmacology·V Claassen
Jul 1, 1983·European Journal of Drug Metabolism and Pharmacokinetics·H OvermarsL C Post
Nov 1, 1984·Archives of General Psychiatry·S R MarderP R May
Jan 1, 1984·Schizophrenia Bulletin·M F Pogue-Geile, M Harrow
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen, S Olsen
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·H J Möller
Oct 1, 1995·Clinical Pharmacology and Therapeutics·O SpigsetR Dahlqvist
Jan 1, 1995·Comprehensive Psychiatry·I BermanA I Green

❮ Previous
Next ❯

Citations

Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Henry SilverMoussa Youdim
Jun 30, 2011·European Journal of Clinical Pharmacology·Amir M NiaFikret Er
Feb 26, 2010·The International Journal of Neuropsychopharmacology·Lena DanovichHenry Silver
May 1, 2003·Expert Review of Neurotherapeutics·Jambur AnanthSarath Gunatilake
Jun 23, 2011·Human Psychopharmacology·Maria VaresErik G Jönsson
Feb 24, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kenji HashimotoMasaomi Iyo
Sep 2, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Eveline Jaquenoud SirotPierre Baumann
Sep 28, 2002·Journal of Clinical Psychopharmacology·Christoph HiemkeHenry Silver
Nov 12, 2005·Journal of Clinical Psychopharmacology·Manabu SaitoSunao Kaneko
Dec 3, 2015·Psychopharmacology·Christoffer Polcwiartek, Jimmi Nielsen
Aug 11, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Margo D M FaayIris E C Sommer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here